Presentation Details:
Dr. Raphael Landovitz provides an update on cabotegravir long-acting (CAB-LA) HIV pre-exposure prophylaxis (PrEP), including data from the HPTN 083 trial and implications for PrEP laboratory testing and monitoring, including HIV RNA monitoring.
Presentation Transcript: